Schizophrenia research and treatment

The paper integrates centenarian genomes and spatio-temporal expression profiles to identify potential drug targets for schizophrenia, suggesting repurposed therapies for neuropsychiatric disorders.

This study uses genome-wide association data for educational attainment and schizophrenia to identify genetic heterogeneity and novel candidate genes for schizophrenia.

This study shows that NR2A-specific NMDAR antagonism increases delta-HFO coupling and decreases theta-HFO coupling, suggesting frontal hyperfunction and hippocampal hypofunction in schizophrenia-like states.

The paper identifies 237 genes associated with schizophrenia using RNA sequencing and eQTL analysis, showing enrichment for developmentally regulated synaptic genes.

The paper finds a genetic association between schizophrenia risk and age at first birth in women, with different genetic correlations in younger and older age groups.

This paper develops a machine learning framework to identify sparse grey matter biomarkers in Schizophrenia and their biological substrates using structural MRI data.

The paper finds a genetic association between schizophrenia risk and urban living, suggesting genetic factors influence migration to densely populated areas.

The paper investigates dysbindin and copper transporter protein abnormalities in schizophrenia substantia nigra, finding altered expression patterns linked to medication status.

The paper identifies TCF4 binding sites and their association with schizophrenia risk genes, showing TCF4 regulates neural development genes and interacts with SZ-related loci.

This study creates a mouse model with a patient-derived NLGN2 R215H mutation, showing GABAergic deficits and schizophrenia-like behaviors.

This study examines how reward influences selective attention in schizophrenia, finding that reaction times are slower in patients but reward and probability effects remain intact.

The paper examines the dynamic expression of risk genes for schizophrenia and bipolar disorder across developmental stages in brain regions, finding distinct expression patterns between the two disorders.

The paper shows that placental gene expression mediates the interaction between obstetrical history and genetic risk for schizophrenia, with ELCs enhancing PRS effects.

The paper maps schizophrenia-associated genomic loci to specific brain cell types using single-cell RNA-sequencing data, finding consistent enrichment in pyramidal cells, medium spiny neurons, and interneurons.

The study examines whether polygenic risk scores for schizophrenia correlate with gene expression in brain tissue but finds no significant associations beyond chance.

This study uses pathway analysis on schizophrenia GWAS data to identify enrichment in synaptic plasticity and neurotransmitter synapse gene sets, supporting a role for postsynaptic signaling in schizophrenia.

This study investigates the role of BRD1 in sex-biased nuclear receptor signaling and its implications in mental disorders using mouse models and gene expression analysis.

This study examines reward prediction error signalling in individuals with first episode psychosis and those at risk for psychosis, finding abnormal midbrain and prefrontal cortex activation compared to healthy controls.

This study investigates decision-making impairments in schizophrenia by analyzing reward prediction error and expected value computations using computational modeling.

This study finds genetic overlap between adolescent psychotic experiences and schizophrenia, bipolar disorder, and major depression using polygenic risk scores and genome-wide association analyses.

The paper reanalyzes exome-sequenced schizophrenia cases and controls, finding significant enrichment of gene sets related to synaptic function, particularly involving FYN and NMDA receptor subunits.

This study uses polygenic scores to show that genetic risk for schizophrenia is linked to increased illicit drug use and age-related increases in substance use among young adults.

The paper matches drug transcriptional signatures to synaptic gene network disruptions to identify known and novel candidate drugs for schizophrenia.

The paper identifies two molecular subtypes of schizophrenia based on differential gene expression in the dorsolateral prefrontal cortex using WGCNA.

The paper examines antibody prevalence against Syncytin-1 in schizophrenia patients using ELISA, finding 50% positivity with high specificity.

The paper identifies an excess of rare loss-of-function and missense mutations in voltage-gated sodium channels and synaptic genes associated with schizophrenia using large-scale sequencing and meta-analysis.

This study investigates conscious perception and attentional processing in schizophrenia using event-related potentials, finding impaired top-down attentional amplification but preserved bottom-up processing.

The paper mutates zebrafish orthologues of schizophrenia-associated genes to identify phenotypic candidates and shared functions.

The paper tests if variants in miR-137 binding sites are associated with schizophrenia using exome sequencing data from 4225 cases and 5834 controls, finding a significant weighted burden test result.

The paper investigates how genetic variation at the NDE1 locus affects gene expression and treatment response to psychiatric medications through interactions with microRNA-484 and CYP2C19.